Key Takeaways Strong growth, innovation, and pricing power are driving high investor expectations for sustained elevated sales and margin improvements despite risks of normalization and market shifts. Optimism about long-term leadership and recurring revenues may not fully account for emerging industry headwinds, evolving clinical practices, or technological disruption risks.Read more
Key Takeaways Rapid success in direct market expansion and premium product launches is driving sustained market share gains, high-margin growth, and likely upward revisions to profitability expectations. Major R&D and automation investments are positioning Medistim for operational excellence and long-term market leadership through clinical innovation and efficiency gains.Read more
Outstanding track record with flawless balance sheet and pays a dividend.
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
